Cencora, Inc. (COR)
(Delayed Data from NYSE)
$237.00 USD
-4.10 (-1.70%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $237.00 0.00 (0.00%) 6:04 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.00 USD
-4.10 (-1.70%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $237.00 0.00 (0.00%) 6:04 PM ET
2-Buy of 5 2
A Value A Growth D Momentum A VGM
Zacks News
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
All You Need to Know About Cencora (COR) Rating Upgrade to Buy
by Zacks Equity Research
Cencora (COR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 5.03% and 0.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
by Indrajit Bandyopadhyay
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?
by Zacks Equity Research
Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Cencora (COR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Embecta Corp. (EMBC): Can Its 6.9% Jump Turn into More Strength?
by Zacks Equity Research
Embecta Corp. (EMBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
by Zacks Equity Research
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
Will High Medical Care Costs Hurt Molina's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina's (MOH) second-quarter performance is likely to have been affected by high medical care costs, partly offset by rising membership in all three businesses.
Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.
Why Cencora (COR) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Cencora (COR) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cencora (COR) Stock Nosedives: Here's What Caused the Decline
by Zacks Equity Research
Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.